 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Supernus Pharmaceuticals
SUPN
note: I will begin coverage with Q2 2025, following acquisition of SAGE
conference date: August 5, 2025 @ 1:30 PM Pacific Time
| 2025 | |||
| Supernus Q2 2025 |
|||
| August 5, 2025 | |||
Supernus is a commercial-stage biotechnology company specializing in central nervous system diseases.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CBIO |
| CCCC |
| CLDX |
| CDTX |
| GILD |
| ILMN |
| IMGN |
| INCY |
| INKT |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| RXRX |
| SAGE |
| SANA |
| SYRS |
| VRTX |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2025 William P. Meyers